Search research articles
Contact Us
Filters
Showing results (221-230 of 277) with videos related to
Page
of 28
Sort By:
Investigational New Drugs
|
November 3, 2021
Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single‑center, multi‑arm phase Ib study
Kyaw Z Thein, Daniel D Karp, Apostolia Tsimberidou, et al.
Investigational New Drugs
|
February 20, 2025
Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm phase Ib study
Kyaw Z Thein, Daniel D Karp, Apostolia Tsimberidou, et al.
Journal of Translational Medicine
|
January 7, 2021
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th, 2019, Naples, Italy)
Paolo A Ascierto, Lisa H Butterfield, Katie Campbell, et al.
Oncotarget
|
November 21, 2017
Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience
Jennifer B Goldstein, Chad Tang, Kenneth R Hess, et al.
Oncotarget
|
September 3, 2016
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy
Haeseong Park, Ignacio Garrido-Laguna, Aung Naing, et al.
Oncotarget
|
May 28, 2015
Clinical next generation sequencing to identify actionable aberrations in a phase I program
Genevieve M Boland, Sarina A Piha-Paul, Vivek Subbiah, et al.
Oncotarget
|
April 19, 2014
MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit
Denis L Fontes Jardim, Debora de Melo Gagliato, Gerald S Falchook, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 13, 2019
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations
Martin H Voss, Cinta Hierro, Rebecca S Heist, et al.
Cancer
|
October 20, 2015
Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies
Rami N Al-Rohil, Ashley J Tarasen, J Andrew Carlson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 19, 2014
Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic
Denis L F Jardim, Chad Tang, Debora De Melo Gagliato, et al.
Page
of 28
Search research articles
Search
Showing results (221-230 of 277) with videos related to
Sort By:
Page
of 28
Investigational New Drugs
|
November 3, 2021
Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single‑center, multi‑arm phase Ib study
Kyaw Z Thein, Daniel D Karp, Apostolia Tsimberidou, et al.
Investigational New Drugs
|
February 20, 2025
Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm phase Ib study
Kyaw Z Thein, Daniel D Karp, Apostolia Tsimberidou, et al.
Journal of Translational Medicine
|
January 7, 2021
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th, 2019, Naples, Italy)
Paolo A Ascierto, Lisa H Butterfield, Katie Campbell, et al.
Oncotarget
|
November 21, 2017
Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience
Jennifer B Goldstein, Chad Tang, Kenneth R Hess, et al.
Oncotarget
|
September 3, 2016
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy
Haeseong Park, Ignacio Garrido-Laguna, Aung Naing, et al.
Oncotarget
|
May 28, 2015
Clinical next generation sequencing to identify actionable aberrations in a phase I program
Genevieve M Boland, Sarina A Piha-Paul, Vivek Subbiah, et al.
Oncotarget
|
April 19, 2014
MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit
Denis L Fontes Jardim, Debora de Melo Gagliato, Gerald S Falchook, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 13, 2019
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations
Martin H Voss, Cinta Hierro, Rebecca S Heist, et al.
Cancer
|
October 20, 2015
Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies
Rami N Al-Rohil, Ashley J Tarasen, J Andrew Carlson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 19, 2014
Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic
Denis L F Jardim, Chad Tang, Debora De Melo Gagliato, et al.
Page
of 28